Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 16/20 | 1.00 |
| ▸ | FFAR4 | Q5NUL3 | 3/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | KDM1A | O60341 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3734035 | 1.00 | FFAR1 (1.00) | FFAR1FFAR4MEN1KMT2AALDH1A1 | |
| SCHEMBL13043552 | 0.90 | FFAR1 (0.81) | FFAR1FFAR4MEN1KMT2AALDH1A1 | |
| SCHEMBL13043488 | 0.86 | FFAR1 (0.75) | FFAR1FFAR4 | |
| SCHEMBL3739736 | 0.86 | FFAR1 (0.75) | FFAR1FFAR4 | |
| SCHEMBL13043524 | 0.83 | FFAR1 (0.71) | FFAR1MEN1KMT2AALDH1A1KDM1A | |
| SCHEMBL3749297 | 0.83 | FFAR1 (0.71) | FFAR1MEN1KMT2AALDH1A1KDM1A | |
| SCHEMBL7868639 | 0.83 | FFAR1 (0.68) | FFAR1FFAR4ALDH1A1KDM1A | |
| SCHEMBL6994406 | 0.83 | FFAR1 (0.68) | FFAR1FFAR4ALDH1A1KDM1A | |
| SCHEMBL3739289 | 0.82 | FFAR1 (0.75) | FFAR1FFAR4 | |
| SCHEMBL3562610 | 0.82 | FFAR1 (0.70) | FFAR1MEN1KMT2AALDH1A1KDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7834013-B2 | Racemic-(trans)-2-[4-({[3-(phenyloxy)phenyl]methyl}ammonium)phenyl]cyclopropanecarboxylic acid; type II diabetes; G protein-coupled receptor 40 (GPR40) agonists | GLAXOSMITHKLINE LLC (US) | 2010-11-16 | — | — | US | disclosed |
| US-7834013-B2 | Racemic-(trans)-2-[4-({[3-(phenyloxy)phenyl]methyl}ammonium)phenyl]cyclopropanecarboxylic acid; type II diabetes; G protein-coupled receptor 40 (GPR40) agonists | GLAXOSMITHKLINE LLC (US) | 2010-11-16 | — | — | US | disclosed |
| US-20090105257-A1 | AMINOPHENYLCYCLOPROPYL CARBOXYLIC ACIDS AND DERIVATIVES AS AGONISTS TO GPR40 | GLAXOSMITHKLINE LLC | 2009-04-23 | — | — | US | disclosed |
| US-20090105257-A1 | AMINOPHENYLCYCLOPROPYL CARBOXYLIC ACIDS AND DERIVATIVES AS AGONISTS TO GPR40 | GLAXOSMITHKLINE LLC | 2009-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105257-A1 | AMINOPHENYLCYCLOPROPYL CARBOXYLIC ACIDS AND DERIVATIVES AS AGONISTS TO GPR40 | GPR65, GPR88, GPR84 | FFAR1 23/4885FFAR4 22/4885MEN1 4331/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.